KalVista Pharmaceuticals (KALV) Retained Earnings (2016 - 2024)
Historic Retained Earnings for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q4 2024 value amounting to -$580.2 million.
- KalVista Pharmaceuticals' Retained Earnings changed N/A to -$580.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$580.2 million, marking a year-over-year change of. This contributed to the annual value of -$469.7 million for FY2024, which is N/A changed from last year.
- KalVista Pharmaceuticals' Retained Earnings amounted to -$580.2 million in Q4 2024.
- In the past 5 years, KalVista Pharmaceuticals' Retained Earnings ranged from a high of -$115.0 million in Q1 2020 and a low of -$580.2 million during Q4 2024
- Over the past 4 years, KalVista Pharmaceuticals' median Retained Earnings value was -$382.2 million (recorded in 2023), while the average stood at -$330.6 million.
- As far as peak fluctuations go, KalVista Pharmaceuticals' Retained Earnings crashed by 3148.49% in 2020, and later tumbled by 3948.7% in 2024.
- Over the past 4 years, KalVista Pharmaceuticals' Retained Earnings (Quarter) stood at -$142.8 million in 2020, then fell by 7.03% to -$152.9 million in 2021, then tumbled by 159.06% to -$396.0 million in 2023, then tumbled by 46.49% to -$580.2 million in 2024.
- Its Retained Earnings was -$580.2 million in Q4 2024, compared to -$552.4 million in Q4 2024 and -$510.2 million in Q3 2024.